Prevention of hypertension in patients with pre-hypertension: protocol for the PREVER-prevention trial

Flávio D Fuchs, Sandra C Fuchs, Leila B Moreira, Miguel Gus, Antônio C Nóbrega, Carlos E Poli-de-Figueiredo, Décio Mion, Luiz Bortoloto, Fernanda Consolim-Colombo, Fernando Nobre, Eduardo Barbosa Coelho, José F Vilela-Martin, Heitor Moreno Jr, Evandro José Cesarino, Roberto Franco, Andréa Araujo Brandão, Marcos R de Sousa, Antônio Luiz Pinho Ribeiro, Paulo Cesar Jardim, Abrahão Afiune Neto, Luiz César N Scala, Marco Mota, Hilton Chaves, João Guilherme Alves, Dario C Sobral Filho, Ricardo Pereira e Silva, José A Figueiredo Neto, Maria Cláudia Irigoyen, Iran Castro, André Avelino Steffens, Rosane Schlatter, Renato Bandeira de Mello, Francisca Mosele, Flávia Ghizzoni, Otávio Berwanger, Flávio D Fuchs, Sandra C Fuchs, Leila B Moreira, Miguel Gus, Antônio C Nóbrega, Carlos E Poli-de-Figueiredo, Décio Mion, Luiz Bortoloto, Fernanda Consolim-Colombo, Fernando Nobre, Eduardo Barbosa Coelho, José F Vilela-Martin, Heitor Moreno Jr, Evandro José Cesarino, Roberto Franco, Andréa Araujo Brandão, Marcos R de Sousa, Antônio Luiz Pinho Ribeiro, Paulo Cesar Jardim, Abrahão Afiune Neto, Luiz César N Scala, Marco Mota, Hilton Chaves, João Guilherme Alves, Dario C Sobral Filho, Ricardo Pereira e Silva, José A Figueiredo Neto, Maria Cláudia Irigoyen, Iran Castro, André Avelino Steffens, Rosane Schlatter, Renato Bandeira de Mello, Francisca Mosele, Flávia Ghizzoni, Otávio Berwanger

Abstract

Background: Blood pressure (BP) within pre-hypertensive levels confers higher cardiovascular risk and is an intermediate stage for full hypertension, which develops in an annual rate of 7 out of 100 individuals with 40 to 50 years of age. Non-drug interventions to prevent hypertension have had low effectiveness. In individuals with previous cardiovascular disease or diabetes, the use of BP-lowering agents reduces the incidence of major cardiovascular events. In the absence of higher baseline risk, the use of BP agents reduces the incidence of hypertension. The PREVER-prevention trial aims to investigate the efficacy, safety and feasibility of a population-based intervention to prevent the incidence of hypertension and the development of target-organ damage.

Methods: This is a randomized, double-blind, placebo-controlled clinical trial, with participants aged 30 to 70 years, with pre-hypertension. The trial arms will be chlorthalidone 12.5 mg plus amiloride 2.5 mg or identical placebo. The primary outcomes will be the incidence of hypertension, adverse events and development or worsening of microalbuminuria and of left ventricular hypertrophy in the EKG. The secondary outcomes will be fatal or non-fatal cardiovascular events: myocardial infarction, stroke, heart failure, evidence of new sub-clinical atherosclerosis, and sudden death. The study will last 18 months. The sample size was calculated on the basis of an incidence of hypertension of 14% in the control group, a size effect of 40%, power of 85% and P alpha of 5%, resulting in 625 participants per group. The project was approved by the Ethics committee of each participating institution.

Discussion: The early use of blood pressure-lowering drugs, particularly diuretics, which act on the main mechanism of blood pressure rising with age, may prevent cardiovascular events and the incidence of hypertension in individuals with hypertension. If this intervention shows to be effective and safe in a population-based perspective, it could be the basis for an innovative public health program to prevent hypertension in Brazil.

Trial registration: Clinical Trials NCT00970931.

Figures

Figure 1
Figure 1
Flow chart of the PREVER-prevention trial, describing selection, randomization and follow-up process.
Figure 2
Figure 2
Summary of the PREVER-Prevention trial key practical aspects.
Figure 3
Figure 3
PREVER-prevention trial cardiovascular outcomes.

References

    1. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–1913. doi: 10.1016/S0140-6736(02)11911-8.
    1. World Health Report 2002. Reducing risks, promoting healthy life. Geneva, Switzerland: World Health Organization; 2002. Accessed October 27, 2010.
    1. Sociedade Brasileira de Cardiologia/Sociedade Brasileira de Hipertensão/Sociedade Brasileira de Nefrologia. VI Brazilian Guidelines of Hypertension. Arq Bras Cardiol. 2010;95(1 supl 1):1–51.
    1. Fuchs FD. Prehypertension: the rationale for early drug therapy. Cardiovasc Ther. 2010;28:339–43. doi: 10.1111/j.1755-5922.2010.00167.x.
    1. Hsia J, Margolis KL, Eaton CB, Wenger NK, Allison M, Wu L, LaCroix AZ, Black HR. Women's Health Initiative Investigators. Pre-hypertension and cardiovascular disease risk in the Women's Health Initiative. Circulation. 2007;115:855–60. doi: 10.1161/CIRCULATIONAHA.106.656850.
    1. Russell LB, Valiyeva E, Carson JL. Effects of pre-hypertension on admissions and deaths: a simulation. Arch Intern Med. 2004;164:2119–24. doi: 10.1001/archinte.164.19.2119.
    1. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665. doi: 10.1136/bmj.b1665.
    1. Guyton AC, Coleman TG, Cowley AV Jr, Scheel KW, Manning RD Jr, Norman RA Jr. Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med. 1972;52:584–94. doi: 10.1016/0002-9343(72)90050-2.
    1. Tobian L. Salt and hypertension. Lessons from animal models that relate to human hypertension. Hypertension. 1991;17(1 Suppl):I52–8.
    1. Dahl LK. In: Genest. Koiw, Kuchel, editor. Hypertension. New York, McGraw Hill; 1977. Salt intake and hypertension; pp. 548–559.
    1. Folkow B, Hallback M, Lundgreen Y, Sivertsson R, Weiss L. Importance of adaptative changes in vascular design for establishment of primary hypertension, studied in man and in spontaneously hypertensive rats. Circ Res. 1973;32(Suppl I):2–16.
    1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217–23.
    1. Leitschuh M, Cupples LA, Kannel W, Gagnon D, Chobanian A. High-normal blood pressure progression to hypertension in the Framingham Heart Study. Hypertension. 1991;17:22–27.
    1. Moreira LB, Fuchs SC, Wiehe M, Gus M, Moraes RS, Fuchs FD. Incidence of hypertension in Porto Alegre, Brazil: a population-based study. J Hum Hypertens. 2008;22:48–50. doi: 10.1038/sj.jhh.1002252.
    1. The Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. Arch Intern Med. 1997;157:657–667. doi: 10.1001/archinte.157.6.657.
    1. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM. et al.A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997;336:1117–1124. doi: 10.1056/NEJM199704173361601.
    1. Premier Collaborative Research Group. Effects of comprehensive lifestyle modification on blood pressure control. JAMA. 2003;289:2083–2093. doi: 10.1001/jama.289.16.2083.
    1. Hooper L, Bartlett C, Davey Smith G, Ebrahim S. Systematic review of long term effects of advice to reduce dietary salt in adults. BMJ. 2002;325:628. doi: 10.1136/bmj.325.7365.628.
    1. Fuchs FD, Gus M, Moreira WD, Moreira LB, Moraes RS, Rosito GA. et al.Blood pressure effects of antyhypertensive drugs and lifestyle modification in a Brazilian hypertensive cohort. J Hypert. 1997;15:783–792. doi: 10.1097/00004872-199715070-00011.
    1. Julius S, Nesbitt S, Egan B, Weber MA, Michelson EL, Kaciroti N. et al.Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354:1685–97. doi: 10.1056/NEJMoa060838.
    1. Lüders S, Schrader J, Berger J, Unger T, Zidek W, Böhm M. et al.The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure - a prospective, randomized, controlled prevention trial of the German Hypertension League. Journal of Hypertension. 2008;26:1487–1496.
    1. Fuchs FD. Blood pressure-lowering drugs: essential therapy for some patients with normal blood pressure. Expert Rev Cardiovasc Ther. 2004;2:771–5. doi: 10.1586/14779072.2.5.771.
    1. Fuchs FD. The corporate bias and the molding of prescription practices: the case of hypertension. Braz J Med Biol Res. 2009;42:224–8.
    1. Fuchs FD. Diuretics: still essential drugs for the management of hypertension. Expert Rev Cardiovasc Ther. 2009;7:591–8. doi: 10.1586/erc.09.32.
    1. Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension. 2000;35:1025–30.
    1. Guerrero P, Fuchs FD, Moreira LM, Martins VM, Bertoluci C, Fuchs SC, Gus M. Blood pressure-lowering efficacy of amiloride versus enalapril as add-on drugs in patients with uncontrolled blood pressure receiving hydrochlorothiazide. Clin Exp Hypertens. 2008;30:553–64. doi: 10.1080/10641960802441906.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi